• On July 21, 2026, Barington Capital escalated its campaign against Chemed, urging a strategic review, cost cuts including executive perks such as personal aircraft use and sporting-event tickets, and proposing a new director to address what it describes as weak oversight.
• The activist’s claim that Chemed houses two strong but under-optimized businesses raises fresh questions about whether current management and board structures are fully unlocking their potential.
• Next, we’ll examine how Barington’s push for a strategic review and tighter cost controls might influence Chemed’s existing investment narrative.

Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.

Chemed Investment Narrative Recap

To own Chemed, you need to believe its two core businesses, VITAS and Roto Rooter, can keep generating solid cash flows despite reimbursement and competition pressures. In the near term, investors are watching for progress on Medicare cap exposure and Roto Rooter margins, while the biggest risk remains reimbursement and mix pressure at VITAS. Barington’s activism challenges cost discipline and governance, but it does not yet appear to change those fundamental drivers in a material way.

Among recent announcements, the expanded US$3,050,000,000 buyback authorization and ongoing repurchases stand out in light of Barington’s call for a strategic review. Management’s willingness to return cash via buybacks, alongside a long dividend record, already speaks to one use of capital that activists might scrutinize or seek to rebalance. How Chemed prioritizes repurchases, debt capacity, and potential hospice acquisitions from here could become more important if activism gains traction.

Yet against this backdrop of steady buybacks and dividends, the concentration of reimbursement risk at VITAS is something investors should be very aware of...

Chemed's narrative projects $3.1 billion revenue and $386.5 million earnings by 2029. This requires 6.6% yearly revenue growth and roughly a $126.7 million earnings increase from $259.8 million today.

Uncover how Chemed's forecasts yield a $474.00 fair value, a 7% downside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were projecting Chemed’s revenue to reach about US$3.1 billion and earnings near US$417.5 million, but Barington’s campaign and the highlighted risk around VITAS reimbursement and admission mix show just how differently you might view the same stock, and why it is worth exploring more than one storyline before you decide what you believe.

Explore 3 other fair value estimates on Chemed - why the stock might be worth 7% less than the current price!

Form Your Own Verdict

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Chemed research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Chemed research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Chemed's overall financial health at a glance.

No Opportunity In Chemed?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Find 49 companies with promising cash flow potential yet trading below their fair value.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.